Study record managers: refer to the Data Element Definitions if submitting registration or results information. Drug: Physician's Best Choice Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate. Other Names: capecitabine eribulin high-dose IV methotrexate.
Electronic address: mfranzoi hcpa. Leptomeningeal carcinomatosis LC is defined as infiltration of the leptomeninges by metastatic carcinoma, a relatively uncommon but devastating complication of many malignancies. It can occur as a late-stage complication of systemic progression or present as the first sign of metastatic disease, with or without parenchymal brain metastases.
Leptomeningeal cancer also called leptomeningeal carcinomatosis, leptomeningeal disease LMDleptomeningeal metastasis, neoplastic meningitis, meningeal metastasis and meningeal carcinomatosis is a rare complication of cancer in which the disease spreads from the original tumor site to the meninges surrounding the brain and spinal cord,  This leads to an inflammatory response, hence the alternative names neoplastic or malignant meningitisor carcinomatous meningitis. It occurs with cancers that are most likely to spread to the central nervous system. Leptomeningeal disease is becoming more evident because cancer patients are living longer and many chemotherapies cannot reach sufficient concentrations in the spinal fluid to kill the tumor cells.
Breast Cancer Research and Treatment. Twenty-two patients with meningeal carcinoma due to breast cancer were restrospectively evaluated to determine what prognostic factors affected survival. Five patients survived for more than one year.
Metrics details. The incidence of meningeal carcinomatosis appears to be higher than in the past due to advances in neuro-imaging diagnostic techniques and improvements in cancer survival. Among solid tumors, breast cancer is the cancer most commonly associated with meningeal carcinomatosis, with an incidence rate of between 0.
Leptomeningeal metastasis LM occurs when solid tumour cells diffusely metastasize to the meninges within the central nervous system CNS 1. It is a manifestation of metastatic disease whereby tumour cells spread through the subarachnoid space 1. Previous studies have reported that the frequency of triple-negative TN breast cancer among LM patients ranges between 21 and
The management and treatment of such patients is poorly-described. We report our experience on breast cancer BC -associated LM and patients with prolonged survival. Results: Combined intra-cerebro spinal fluid CSF and systemic treatment were administered until disease progression or toxicity in all but two patients. Involved-field radiotherapy was administered to two patients.
There is limited data on the impact of specific patient characteristics, tumor subtypes or treatment interventions on survival in breast cancer LM. A systematic review was conducted to assess the impact of hormone receptor and HER-2 status on survival in breast cancer LM. Survival data from all studies are reported by study design prospective trials, retrospective cohort studies, case studies.